Biopharma in 2019

Biopharma in 2019

Ash 2018 preview – blood cancers offer biotech a chance at redemption

The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.   Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!! For biotech the past month or so has been ugly. The Esmo meeting … Συνεχίστε να διαβάζετε Ash 2018 preview – blood cancers offer biotech a chance at redemption.

Gene therapy deal-making shows no signs of stopping

Gene therapy deal-making shows no signs of stopping

The 2018 pipeline report: Aspiring assets to keep an eye on

Looking ahead to 2018, the most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch. Consumers are more sensitive than ever to high prices, with more than 30 states introducing legislation on drug pricing. Given the current political … Συνεχίστε να διαβάζετε The 2018 pipeline report: Aspiring assets to keep an eye on.

What do the CAR-T Patient Deaths Mean for the Future of the Field?

Juno’s JCAR015 study came to a halt for the second time this year after two more patient deaths. But despite the bad news, hopes for CAR-T therapies remain high.  Juno Therapeutics again came under scrutiny last month following deaths in its JCAR015 trial. Two patients died from neurotoxicity-triggered cerebral edema, the same condition that killed … Συνεχίστε να διαβάζετε What do the CAR-T Patient Deaths Mean for the Future of the Field?.